http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009151295-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24430c627c7e011dc7560cb085ee51b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e559743173473475142b7bd8a978298 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28627059e1e1bdd2890ef9b952b82b8a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e23a4c9cd982ccdb6082585045b94b7a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c33460821110221bacdadf125aab6895 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
| filingDate | 2009-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_801090d3d41d51a862b4094a43f388fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3abf9c288d73274ff516b11a80ea939b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f002c73b2bbfeefdddce5bdd1b4e07df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d61192fd8d1dd3ecd28a50e6cfbc46a9 |
| publicationDate | 2009-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2009151295-A2 |
| titleOfInvention | Pharmaceutical formulation comprising azelnidipine and hmg-coa reductase inhibitor or angiotensin ii receptor blocker |
| abstract | Disclosed is a controlled-release pharmaceutical formulation comprising azelnidipine and HMG-CoA reductase inhibitor or an angiotensin II receptor blocker, wherein as it takes a different amount of time to exhibit a pharmacological effect of each individual ingredient of the pharmaceutical formulation in a human body, each of the ingredients can be control-released at a specific rate to exhibit the optimum effect on absorption in the human body. The pharmaceutical formulation of the present invention is highly effective in treating hypertension and preventing its complications in persons having a so-called metabolic syndrome, which is present as a complex of hyperlipidemia, coronary artery disease, heart disease, kidney disease or cerebrovascular disease, etc., wherein, by increasing patient compliance, the impact on external factors can also be maximized. |
| priorityDate | 2008-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 485.